A nurse is providing teaching for a postpartum client who has a new prescription for carboprost

1. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38–47. [PubMed] [Google Scholar]

2. ACOG Committee Opinion, authors. Number 283, May 2003. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy. Obstet Gynecol. 2003;101:1049–1050. [PubMed] [Google Scholar]

3. Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception. 2006;74:26–30. [PubMed] [Google Scholar]

4. Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92. [PubMed] [Google Scholar]

5. Danielsson KG, Marions L, Rodriguez A, et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93:275–280. [PubMed] [Google Scholar]

6. Khan RU, El-Refaey H, Sharma S, et al. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol. 2004;103:866–870. [PubMed] [Google Scholar]

7. Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332–336. [PubMed] [Google Scholar]

8. Singh K, Fong YF, Prasad RN, Dong F. Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming? Hum Reprod. 1999;14:1635–1637. [PubMed] [Google Scholar]

9. Creinin MD, Carbonell JL, Schwartz JL, et al. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999;59:11–16. [PubMed] [Google Scholar]

10. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod. 2004;19:81–84. [PubMed] [Google Scholar]

11. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception. 2005;71:22–25. [PubMed] [Google Scholar]

12. Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet Gynecol. 2006;108:582–590. [PubMed] [Google Scholar]

13. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks gestation. Hum Reprod. 2005;20:3072–3077. [PubMed] [Google Scholar]

14. Li CF, Wong CY, Chan CP, Ho PC. A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. Contraception. 2003;67:101–105. [PubMed] [Google Scholar]

15. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG. 2000;107:519–523. [PubMed] [Google Scholar]

16. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol. 2005;105:1203–1205. [PubMed] [Google Scholar]

17. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(suppl 2):S160–S167. [PubMed] [Google Scholar]

18. Pastuszak AL, Schüler L, Speck-Martins CE, et al. Use of misoprostol during pregnancy and Möbius’ syndrome in infants. N Engl J Med. 1998;338:1881–1885. [PubMed] [Google Scholar]

19. Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol. 2004;191:2168–2173. [PubMed] [Google Scholar]

20. Hale TW. Medications and Mothers’ Milk. 11th ed. Amarillo, TX: Pharmasoft Publishing; 2004. [Google Scholar]

21. Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006;74:66–86. [PubMed] [Google Scholar]

22. National Abortion Federation (NAF), authors NAF Protocol for Mifepristone/Misoprostol in Early Abortion. Washington, DC: National Abortion Federation; 2008. [Accessed January 15, 2009]. http://www.prochoice.org/pubs_research/publications/downloads/professional_education/medical_abortion/protocol_mife_miso.pdf. [Google Scholar]

23. Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol. 2008;112:1303–1310. [PubMed] [Google Scholar]

24. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol. 2000;183(2 suppl):S34–S43. [PubMed] [Google Scholar]

25. Walker K, Schaff E, Fielding S, Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception. 2001;64:271–273. [PubMed] [Google Scholar]

26. Davey A. Mifepristone and prostaglandin for termination of pregnancy: contraindications for use, reasons and rationale. Contraception. 2006;74:16–20. [PubMed] [Google Scholar]

27. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol. 2000;183(2 suppl):S65–S75. [PubMed] [Google Scholar]

28. Henderson JT, Hwang AC, Harper CC, Stewart FH. Safety of mifepristone abortions in clinical use. Contraception. 2005;72:175–178. [PubMed] [Google Scholar]

29. Moreno-Ruiz NL, Borgatta L, Yanow S, et al. Alternatives to mifepristone for early medical abortion. Int J Gynaecol Obstet. 2007;96:212–218. [PubMed] [Google Scholar]

30. Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103:729–737. [PubMed] [Google Scholar]

31. Royal College of General Practitioners, Royal College of Obstetricians and Gynaecologists, authors. Induced abortion operations and their early sequelae. J R Coll Gen Pract. 1985;35:175–180. [PMC free article] [PubMed] [Google Scholar]

32. Cates W , Jr, Schulz KF, Grimes DA. The risks associated with teenage abortion. N Engl J Med. 1983;309:621–624. [PubMed] [Google Scholar]

33. Grimes DA, Schulz KF, Cates WJ., Jr Prevention of uterine perforation during curettage abortion. JAMA. 1984;251:2108–2111. [PubMed] [Google Scholar]

34. Schulz KF, Grimes DA, Cates W., Jr Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983;1:1182–1185. [PubMed] [Google Scholar]

35. Allen RH, Goldberg AB Board of Society of Family Planning, authors. Cervical dilation before first-trimester surgical abortion (<14 weeks’ gestation). SFP Guideline 20071. Contraception. 2007;76:139–156. [PubMed] [Google Scholar]

36. Blanchard K, Clark S, Winikoff B, et al. Misoprostol for women’s health: a review. Obstet Gynecol. 2002;99:316–332. [PubMed] [Google Scholar]

37. Singh K, Fong YF. Preparation of the cervix for surgical termination of pregnancy in the first trimester. Hum Reprod Update. 2000;6:442–448. [PubMed] [Google Scholar]

38. Carbonell JL, Velazco A, Rodriguez Y, et al. Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. Eur J Contracept Reprod Health Care. 2001;6:134–140. [PubMed] [Google Scholar]

39. MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766–770. [PubMed] [Google Scholar]

40. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol. 2004;190:55–59. [PubMed] [Google Scholar]

41. Fiala C, Gemzell-Danielsson K, Tang OS, von Hertzen H. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynaecol Obstet. 2007;99(suppl 2):S168–S171. [PubMed] [Google Scholar]

42. Saxena P, Salhan S, Sarda N. Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003;67:213–217. [PubMed] [Google Scholar]

43. Ngai SW, Tang OS, Lao T, et al. Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod. 1995;10:1220–1222. [PubMed] [Google Scholar]

44. Fox MC, Hayes JL Society of Family Planning, authors. Cervical preparation for second-trimester surgical abortion prior to 20 weeks of gestation. Contraception. 2007;76:486–495. [PubMed] [Google Scholar]

45. Todd CS, Soler M, Castleman L, et al. Buccal misoprostol as cervical preparation for second trimester pregnancy termination. Contraception. 2002;65:415–418. [PubMed] [Google Scholar]

46. Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception. 2006;73:420–430. [PubMed] [Google Scholar]

47. Goldberg AB, Drey EA, Whitaker AK, et al. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005;106:234–241. [PubMed] [Google Scholar]

48. Edelman AB, Buckmaster JG, Goetsch MF, et al. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. Am J Obstet Gynecol. 2006;194:425–430. [PubMed] [Google Scholar]

49. Nucatola D, Roth N, Saulsberry V, Gatter M. Serious adverse events associated with the use of misoprostol alone for cervical preparation prior to early second trimester surgical abortion (12–16 weeks) Contraception. 2008;78:245–248. [PubMed] [Google Scholar]

50. Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol. 2002;14:409–415. [PubMed] [Google Scholar]

51. Crane JM, Healey S. Use of misoprostol before hysteroscopy: a systematic review. J Obstet Gynaecol Can. 2006;28:373–379. [PubMed] [Google Scholar]

52. Batukan C, Ozgun MT, Ozcelik B, et al. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol. Fertil Steril. 2008;89:966–973. [PubMed] [Google Scholar]

53. Oppegaard KS, Nesheim BI, Istre O, Qvigstad E. Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design. BJOG. 2008;115:663. [PMC free article] [PubMed] [Google Scholar]

54. Preutthipan S, Herabutya Y. A randomized controlled trial of vaginal misoprostol for cervical priming before hysteroscopy. Obstet Gynecol. 1999;94:427–430. [PubMed] [Google Scholar]

55. Preutthipan S, Herabutya Y. Vaginal misoprostol for cervical priming before operative hysteroscopy: a randomized controlled trial. Obstet Gynecol. 2000;96:890–894. [PubMed] [Google Scholar]

56. Ngai SW, Chan YM, Liu KL, Ho PC. Oral misoprostol for cervical priming in non-pregnant women. Hum Reprod. 1997;12:2373–2375. [PubMed] [Google Scholar]

57. Waddell G, Desindes S, Takser L, et al. Cervical ripening using vaginal misoprostol before hysteroscopy: a double-blind randomized trial. J Minim Invasive Gynecol. 2008;15:739–744. [PubMed] [Google Scholar]

58. Singh N, Ghosh B, Naha M, Mittal S. Vaginal misoprostol for cervical priming prior to diagnostic hysteroscopy-efficacy, safety and patient satisfaction: a randomized controlled trial. Arch Gynecol Obstet. 2009;279:37–40. [PubMed] [Google Scholar]

59. Fernandez H, Alby JD, Tournoux C, et al. Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a double-blind, placebo-controlled trial with three dose regimens. Hum Reprod. 2004;19:1618–1621. [PubMed] [Google Scholar]

60. Barcaite E, Bartusevicius A, Railaite DR, Nadisauskiene R. Vaginal misoprostol for cervical priming before hysteroscopy in perimenopausal and postmenopausal women. Int J Gynaecol Obstet. 2005;91:141–145. [PubMed] [Google Scholar]

61. Fung TM, Lam MH, Wong SF, Ho LC. A randomised placebo-controlled trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women. BJOG. 2002;109:561–565. [PubMed] [Google Scholar]

62. Ngai SW, Chan YM, Ho PC. The use of misoprostol prior to hysteroscopy in postmenopausal women. Hum Reprod. 2001;16:1486–1488. [PubMed] [Google Scholar]

63. Thomas JA, Leyland N, Durand N, Windrim RC. The use of oral misoprostol as a cervical ripening agent in operative hysteroscopy: a double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2002;186:876–879. [PubMed] [Google Scholar]

64. Perrone JF, Caldito G, Mailhes JB, et al. Oral misoprostol before office endometrial biopsy. Obstet Gynecol. 2002;99:439–444. [PubMed] [Google Scholar]

65. Sääv I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod. 2007;22:2647–2652. [PubMed] [Google Scholar]

66. Chen BA, Creinin MD. Contemporary management of early pregnancy failure. Clin Obstet Gynecol. 2007;50:67–88. [PubMed] [Google Scholar]

67. Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks) Cochrane Database Syst Rev. 2006;3 CD002253. [PMC free article] [PubMed] [Google Scholar]

68. Consensus Statement, authors. Instructions for Use-Misoprostol for the Treatment of Incomplete Abortion and Miscarriage; Expert Meeting on Misoprostol; June 9, 2004; New York: Reproductive Health Technologies Project and Gynuity Health Projects; 2008. [Google Scholar]

69. Zhang J, Gilles JM, Barnhart K, et al. National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial, authors. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353:761–769. [PubMed] [Google Scholar]

70. Lee DT, Cheung LP, Haines CJ, et al. A comparison of the psychologic impact and client satisfaction of surgical treatment with medical treatment of spontaneous abortion: a randomized controlled trial. Am J Obstet Gynecol. 2001;185:953–958. [PubMed] [Google Scholar]

71. Reeves MF, Lohr PA, Harwood BJ, Creinin MD. Ultrasonographic endometrial thickness after medical and surgical management of early pregnancy failure. Obstet Gynecol. 2008;111:106–112. [PubMed] [Google Scholar]

72. Carbonell JL, Torres MA, Reyes R, et al. Secondtrimester pregnancy termination with 600-microg vs. 400-microg vaginal misoprostol and systematic curettage postexpulsion: a randomized trial. Contraception. 2008;77:50–55. [PubMed] [Google Scholar]

73. Wong KS, Ngai CS, Yeo EL, et al. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod. 2000;15:709–712. [PubMed] [Google Scholar]

74. Herabutya Y, Chanrachakul B, Punyavachira P. A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination. BJOG. 2005;112:1297–1301. [PubMed] [Google Scholar]

75. Herabutya Y, Chanrachakul B, Punyavachira P. Second trimester pregnancy termination: a comparison of 600 and 800 micrograms of intravaginal misoprostol. J Obstet Gynaecol Res. 2001;27:125–128. [PubMed] [Google Scholar]

76. Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol. 2002;186:470–474. [PubMed] [Google Scholar]

77. Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2007;110:1304–1310. [PubMed] [Google Scholar]

78. Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol. 2003;101:1294–1299. [PubMed] [Google Scholar]

79. Daskalakis GJ, Mesogitis SA, Papantoniou NE, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG. 2005;112:97–99. [PubMed] [Google Scholar]

80. Bhattacharjee N, Ganguly RP, Saha SP. Misoprostol for termination of mid-trimester post-Caesarean pregnancy. Aust N Z J Obstet Gynaecol. 2007;47:23–25. [PubMed] [Google Scholar]

81. Fletcher HM, Mitchell S, Simeon D, et al. Intravaginal misoprostol as a cervical ripening agent. Br J Obstet Gynaecol. 1993;100:641–644. [PubMed] [Google Scholar]

82. Ngai SW, To WK, Lao T, Ho PC. Cervical priming with oral misoprostol in pre-labor rupture of membranes at term. Obstet Gynecol. 1996;87:923–926. [PubMed] [Google Scholar]

83. Alfirevic Z. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2001;2 CD001338. [PubMed] [Google Scholar]

84. Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2004;4 CD004221. [PMC free article] [PubMed] [Google Scholar]

85. Hofmeyr GJ, Gülmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2003 CD000941. [PubMed] [Google Scholar]

86. Sanchez-Ramos L, Kaunitz AM. Misoprostol for cervical ripening and labor induction: a systematic review of the literature. Clin Obstet Gynecol. 2000;43:475–488. [PubMed] [Google Scholar]

87. Wing DA, Gaffaney CA. Vaginal misoprostol administration for cervical ripening and labor induction. Clin Obstet Gynecol. 2006;49:627–641. [PubMed] [Google Scholar]

88. Bamigboye AA, Hofmeyr GJ, Merrell DA. Rectal misoprostol in the prevention of postpartum hemorrhage: a placebo-controlled trial. Am J Obstet Gynecol. 1998;179:1043–1046. [PubMed] [Google Scholar]

89. Hofmeyr GJ, Nikodem VC, de Jager M, Gelbart BR. A randomised placebo controlled trial of oral misoprostol in the third stage of labour. Br J Obstet Gynaecol. 1998;105:971–975. [PubMed] [Google Scholar]

90. Surbek DV, Fehr PM, Hösli I, Holzgreve W. Oral misoprostol for third stage of labor: a randomized placebo-controlled trial. Obstet Gynecol. 1999;94:255–258. [PubMed] [Google Scholar]

91. El-Refaey H, O’Brien P, Morafa W, et al. Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol. 1997;104:336–339. [PubMed] [Google Scholar]

92. Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007;3 CD000494. [PubMed] [Google Scholar]

93. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007;1 CD003249. [PubMed] [Google Scholar]

94. O’Brien P, El-Refaey H, Gordon A, et al. Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Obstet Gynecol. 1998;92:212–214. [PubMed] [Google Scholar]